Meeting
2019 ASCO Annual Meeting
The DIAL Study (Dual Immunomodulation in Aggressive Lymphoma): A randomized phase 2 study of CDX-1127 (varlilumab) in combination with nivolumab in patients with relapsed or refractory aggressive B-cell lymphomas (NCI 10089/NCT03038672).
Authors
Jose Caetano Villasboas
Mayo Clinic, Rochester, MN
Jose Caetano Villasboas , Craig B. Reeder , Han W. Tun , Nancy L. Bartlett , Elad Sharon , Betsy LaPlant , Alex A. Adjei , Stephen M. Ansell
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Sub Track
Non-Hodgkin Lymphoma
Clinical Trial Registration Number
NCT03038672
Citation
J Clin Oncol 37, 2019 (suppl; abstr TPS7570)
DOI
10.1200/JCO.2019.37.15_suppl.TPS7570
Abstract #
TPS7570
Poster Bd #
322a
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Results of the DIAL study (NCI 10089), a randomized phase 2 trial of varlilumab combined with nivolumab in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma (r/r B-NHL).
First Author: Jose Caetano Villasboas
Poster
2022 ASCO Annual Meeting
KEYNOTE B68: Open-label phase 2 study of the efficacy and safety of pembrolizumab administered every six weeks in patients with relapsed or refractory classical Hodgkin lymphoma or primary mediastinal B-cell lymphoma.
First Author: Philippe Armand
Poster
2021 Gastrointestinal Cancers Symposium
Phase II trial of nivolumab and metformin in patients with treatment refractory microsatellite stable metastatic colorectal cancer.
First Author: Mehmet Akce
Poster
2019 ASCO Annual Meeting
A phase I trial using CD19 CAR-T expressing PD-1/CD28 chimeric switch-receptor for refractory or relapsed B-cell lymphoma.
First Author: Hui Liu